Oligonucleotide IMT504 induces an immunogenic phenotype and apoptosis in chronic lymphocytic leukemia cells

Medicina

Volumn 66, Issue 1, 2006, Pages 9-16

  Rodrigues, Juan M ^a   Elias, Fernanda ^b   Montaner, Alejandro ^a   Flo, Juan ^b   Lopez, Ricardo A ^c   Zorzopulos, Jorge ^a   Franco, Raul J ^c   Lenial, Silvina P ^c   Lopez Salón, Mariella ^c   Pirpignani, Maria L ^c   Solimano, Jorge ^d   Garay, Guy ^d   Riveros, Dardo ^d   Fernandez, Jose ^d   Cacchione, Roberto ^d   Dupont, Juan ^d  

^a Fundacion Pablo Cassara   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c Immunotech SA   (Argentina)

^d CEMIC   (Argentina)

Author keywords

Chronic lymphocytic leukemia; IL 2; Immunogenic phenotype; Immunostimulatory ODN; VH genes mutation

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR ALPHA; OLIGODEOXYNUCLEOTIDE; RECOMBINANT INTERLEUKIN 2;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE ACTIVATION; CANCER GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE MARKER; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOGENICITY; IN VITRO STUDY; INCUBATION TIME; LEUKEMIA CELL; MALE; MIXED LYMPHOCYTE REACTION; PHENOTYPE; PRIMATE; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; UPREGULATION;

AGED; ANTIGENS, CD; APOPTOSIS; FEMALE; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; MUTATION; OLIGODEOXYRIBONUCLEOTIDES; PHENOTYPE; POLYMERASE CHAIN REACTION;

EID: 33645125512     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102: 1515-25.
2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-54.
3. Decker T, Flohr T, Trautmann P, et al. Role of accessory cells in cytokine production by T cells in chronic B-cell lymphocytic leukemia. Blood 1995; 86: 1115-21
4. Dazzi F, D'Andrea E, Biasi G, et al. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol 1995; 75: 26-32.
5. Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 1993; 177: 925-35.
6. Van den Hove LE, Van Gool SW, Vandenberghe P, et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia. 1997; 11: 572-80.
7. Kato K, Cantwell MJ, Sharma S, Kipps TJ. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998; 101: 1133-41.
8. Wierda WG, Cantwell MJ, Woods SJ, et al. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia, Blood 2000; 96: 2917-24.
9. Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000; 95: 999-1006.
10. Jahrsdorfer B, Hartmann G, Racila E, et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001; 69: 81-8.
11. Decker T, Scneller F, Kronschnabl M, et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: Costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 2000; 28: 558-68.
12. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-9.
13. Kadowaki N, Antonenko S, Liu YJ. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol 2001; 166: 2291-5.
14. Krug A, Rothenfusser S, Hornung V, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 2001; 31: 2154-63.
15. Krug A, Towarowski A, Britsch S, et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31: 3026-37.
16. Hartmann G, Krieg AM. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 2000; 164: 944-53.
17. Sparwasser T, Koch ES, Vabulas RM, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998; 28: 2045-54.
18. Ballas ZK, Rasmussen WL, Krieg AM. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 1996; 157: 1840-5.
19. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531-7.
20. Lipford GB, Bauer M, Blank C, et al. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. Eur J Immunol 1997; 27: 2340-4.
21. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186: 1623-31.
22. Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998; 16: 1216-24.
23. Davis HL, Weeratna R, Waldschmidt TJ, et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 1998; 160: 870-6.
24. Weeratna RD, McCluskie MJ, Xu Y, Davis HL. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000; 18: 1755-62.
25. Kline JN Waldschmidt TJ, Businga TR, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160: 2555-9.
26. Magone MT, Chan CC, Beck L, Whitcup SM, Raz E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol 2000; 30: 1841-50.
27. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997; 89: 2994-98.
28. Carpentier AF, Chen L, Maltonti F, Delattre JY. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastorna in mice. Cancer Res 1999; 59: 5429-32.
29. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-60.
30. Elias F, Flo J, Lopez RA, et al. Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol 2003; 171: 3697-3704.
31. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052-7.
32. Weisenburger DD, Armitage JO. Mantle cell lymphomaan entity comes of age. Blood 1996; 87: 4483-94.
33. Flo J, Massouh E. Age-related changes of naive and memory CD4 rat lymphocyte subsets in mucosal and systemic lymphoid organs. Dev Comp Immunol 1997; 21: 443-53.
34. Cook GP, Tomlinson IM. The human immunoglobulin VH repertoire. Immunol Today 1995; 16: 237-42.
35. Chang B, Casali P. The CDR1 sequences of a major proportion of human germline Ig VH genes are inherently susceptible to amino acid replacement. Immunol Today 1994; 15: 367-73.
36. Buhmann R, Nolte A, Westhaus D, Emmerich B, Hallek M. CD40-activated B-Cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generate different types of effector cells. Blood 1999; 93: 1992-2002.
37. Collins RJ, Verschuer LA, Harmon BV, et al. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukemia cells following their culture in vitro. Br J Haematol 1989; 71: 343-50.
38. McConkey DJ, Aguilar-Santelises M, Hartzell P, et al. Induction of DNA fragmentation in chronic B-lymphocytic leukemia cells. J Immunol 1991; 146: 1072-6.
39. Yi AK, Peckham DW, Ashman RF, Krieg AM. CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int Immunol 1999; 11: 2015-24.
40. Wang Z, Karras JG, Colarusso TP, Foote LC, Rothstein TL. Unmethylated CpG motifs protect murine B lymphocytes against Fas-mediated apoptosis. Cell Immunol 1997; 180: 162-7.